Postoperative Weight Gain May Contribute to Development of Lymphedema
the Cancer Therapy Advisor take:
Postoperative weight gain during treatment of breast cancer is an important factor for both the patient’s development of lymphedema and response to treatment, according to an article published online in the journal Supportive Care in Cancer.
In this study, the files of patients with breast cancer-related lymphedema (from 2006 to 2012) were analyzed retrospectively, and patient demographics, clinical variables, patient variables, and circumference measurements (of lymphedema and healthy arms) were recorded.
A total of 331 patients were evaluated, with an average age of 54.4 ± 10.9 years and an average length of lymphedema treatment of 2.92 ± 1.3 weeks.
Results showed postoperative weight gain was significantly associated with postoperative duration, number of chemotherapy (CT) cycles, duration of tamoxifen use, and duration of hormonal therapy (P<0.05). The authors found a statistically significant negative correlation between post-treatment arm volume and activity level, postoperative duration, and postoperative weight gain (P<0.05).
Furthermore, the investigators concluded that the breast cancer treatment methods had no effect on patients’ response to treatment of lymphedema.
The study suggests its findings, specifically the correlation between activity level and postoperative weight gain, may provide guidance in clinical practice.
Postoperative weight gain during treatment of breast cancer is an important factor for both the patient’s development of lymphedema.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pancreatitis and the Risk of Cancer
- RAMIE May Improve Post-operative Outcomes Among Patients With Esophageal Cancer
- Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- CTC Screening May Be Effective Method for Preventing Colorectal Cancer
- Physical Activity Intervention May Improve Functional Well-being Among CRC Survivors
- Atezolizumab With Cobimetinib Yields Partial Response in Small Number of Patients With CRC
- Nivolumab May Improve Long-term Complete Response Rate in Subset of Patients With mCRC
- Alcohol Consumption and Cancer